Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.62 |
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10300269 | 1.00 | PTGS2 (0.62) | PTGS2ENPP2KIF11CA12CA2 | |
| SCHEMBL2376239 | 0.90 | ENPP2 (0.72) | PTGS2ENPP2 | |
| SCHEMBL8770202 | 0.89 | PTGS2 (0.79) | PTGS2CA12CA2CA9PTGS1 | |
| SCHEMBL1687503 | 0.89 | PTGS2 (0.79) | PTGS2CA12CA2CA9PTGS1 | |
| SCHEMBL12341698 | 0.89 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL15771185 | 0.87 | ENPP2 (0.56) | PTGS2ENPP2KIF11 | |
| SCHEMBL5052857 | 0.87 | PTGS2 (0.74) | PTGS2KIF11PTGS1 | |
| SCHEMBL7395459 | 0.87 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL6470141 | 0.87 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL10058341 | 0.87 | PTGS2 (0.52) | PTGS2ENPP2KIF11PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113093-A1 | Polymers with reduced estrogenic activity | SOLVAY SPECIALITY POLYMERS USA, LLC (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113093-A1 | Polymers with reduced estrogenic activity | SOLVAY SPECIALITY POLYMERS USA, LLC (US) | 2014-04-24 | — | — | US | disclosed |
| US-8648094-B2 | IAP BIR domain binding compounds | PHARMASCIENCE, INC. (CA) | 2014-02-11 | — | — | US | disclosed |
| WO-2012160172-A1 | POLYMERS WITH REDUCED ESTROGENIC ACTIVITY | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120195915-A1 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-08-02 | — | — | US | disclosed |
| EP-1320785-B1 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | BASF SE (DE) | 2010-02-17 | — | — | EP | disclosed |
| US-7250483-B2 | Inhibition of catalytically active impurities in polycarbonate by the melt transesterification process | BAYER MATERIALSCIENCE AG (DE) | 2007-07-31 | — | — | US | disclosed |
| US-7244544-B2 | Oxime derivatives and the use thereof as latent acids | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244544-B2 | Oxime derivatives and the use thereof as latent acids | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195915-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | PTGS2 4275/4885ENPP2 1514/4885KIF11 2050/4885 |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | PTGS2 199/4885ENPP2 626/4885KIF11 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.